

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 22, 2026 (the “**Prospectus**”) issued by Guangdong True Health Medical Technology Development Co., Ltd. (廣東真健康醫療科技開發股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of our Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about our Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or maintaining the market price of the Offer Shares at a level higher than that which might otherwise prevail in the open market for a limited period after the Listing Date. However, as there has been no over-allocation in the International Offering, there will not be any stabilization activities to be undertaken by the Stabilizing Manager after the Listing in connection with the Global Offering.

Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall, in their sole and absolute discretion, be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, June 30, 2026).



**Guangdong True Health Medical
Technology Development Co., Ltd.**

廣東真健康醫療科技開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 3,564,700 H Shares
Number of Hong Kong Offer Shares	: 356,480 H Shares
Number of International Offer Shares	: 3,208,220 H Shares
Final Offer Price	: HK\$126.20 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%
Nominal Value	: RMB1.00 per H Share
Stock code	: 2697

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers*



**Guangdong True Health Medical
Technology Development Co., Ltd.**
廣東真健康醫療科技開發股份有限公司

ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Prospectus issued by the Company.

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company Information	
Stock Code	2697
Stock Short Name	TH MEDICAL-B
Dealings commencement date	June 30, 2026*

* see note at the end of the announcement

Price Information	
Final Offer Price	HK\$126.20

Offer Shares and Share Capital	
Number of Offer Shares	3,564,700 H Shares
Number of Offer Shares in Hong Kong Public Offering	356,480 H Shares
Number of Offer Shares in International Offering	3,208,220 H Shares
Number of issued Shares upon Listing	35,647,003 H Shares

Over-allocation	
Number of Offer Shares over-allocated	0

Note: There has been no over-allocation of Offer Shares in the International Offering. Therefore, (i) the Over-allotment Option will not be exercised and will lapse upon Listing; and (ii) there will not be any stabilization activities to be undertaken by the Stabilizing Manager after the Listing in connection with the Global Offering.

Proceeds	
Gross proceeds ^(Note)	HK\$449.9 million
Less: Estimated listing expenses payable based on Final Offer Price	HK\$65.9 million
Net Proceeds	HK\$384.0 million

Note: Gross proceeds refers to the amount which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	128,208
No. of successful applications	15,453
Subscription level	1,790.4 times
Reallocation	N/A
No. of Offer Shares initially available under the Hong Kong Public Offering	356,480
No. of Offer Shares allocated from the International Offering	0
Final no. of Offer Shares under the Hong Kong Public Offering	356,480
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	10.00%

Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to the “Allotment Results” page at the designated results of allocation at <https://www.hkeipo.hk/iporesult> or <https://www.hkeipo.hk/IPOResult> with a “search by ID” function.

INTERNATIONAL OFFERING

No. of places	107
Subscription Level	2.2 times
No. of Offer Shares initially available under the International Offering	3,208,220
No. of Offer Shares reallocated to the Hong Kong Public Offering	0
Final no. of Offer Shares under the International Offering	3,208,220
% of Offer Shares under the International Offering to the Global Offering	90.00%

The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

LOCK-UP UNDERTAKINGS

Controlling Shareholders

<i>Name</i> ^{Note 1}	<i>No. of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>% of total issued share capital of the Company subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>Last day subject to the lock-up undertakings</i> ^{Note 2}
Guangdong Hengqin Renyang Biotechnology Center (Limited Partnership)* (廣東橫琴任陽生物科技中心(有限合夥)) ("Renyang Biotechnology") ^{Note 3}	3,360,000	9.43%	9.43%	June 29, 2027
Zhuhai Chengzhen Health Technology Partnership (Limited Partnership)* (珠海誠真健康科技合夥企業(有限合夥)) ("Chengzhen Health") ^{Note 3}	3,000,000	8.42%	8.42%	June 29, 2027
Zhuhai Jiarun Tongchuang Technology Development Partnership (Limited Partnership)* (珠海嘉潤同創科技發展合夥企業(有限合夥)) ("Jiarun Tongchuang") ^{Note 3}	2,400,000	6.73%	6.73%	June 29, 2027
Zhuhai Jiarun Hechuang Technology Development Partnership (Limited Partnership)* (珠海嘉潤合創科技發展合夥企業(有限合夥)) ("Jiarun Hechuang") ^{Note 3}	2,293,900	6.44%	6.44%	June 29, 2027

<i>Name</i> ^{Note 1}	<i>No. of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>% of total issued share capital of the Company subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>Last day subject to the lock-up undertakings</i> ^{Note 2}
Zhuhai Meijirui Medical Technology Partnership (Limited Partnership)* (珠海美吉睿醫療科技合夥企業(有限合夥)) (“Zhuhai Meijirui”) ^{Note 3}	2,071,682	5.81%	5.81%	June 29, 2027
Zhuhai Jiarun Xinchuang Technology Development Partnership (Limited Partnership)* (珠海嘉潤新創科技發展合夥企業(有限合夥)) (“Jiarun Xinchuang”) ^{Note 3}	1,800,000	5.05%	5.05%	June 29, 2027
Xinhui Runkang (Zhuhai Hengqin) Investment Consulting Center (Limited Partnership)* (欣慧潤康(珠海橫琴)投資諮詢中心(有限合夥)) (“Xinhui Runkang”) ^{Note 3}	33,650	0.09%	0.09%	June 29, 2027
Subtotal of Controlling Shareholders	14,959,232	41.96%	41.96%	
* For identification purposes only Notes: 1. For illustrative purposes only, this subsection lists only those members of the Controlling Shareholders who hold H Shares directly in the Company. 2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The required lock-up for existing Shareholders ends on June 29, 2027, being 12 months following the Listing Date. Pursuant to Rule 10.07 of the Listing Rules, each of the Controlling Shareholders has undertaken to the Stock Exchange and the Company that, she or it shall comply with the applicable lock-up requirements. For further details, please refer to the section headed “Underwriting – Underwriting Arrangements – Lock Up Arrangement – Undertakings to the Stock Exchange Pursuant to the Listing Rules – (B) Undertakings by the Controlling Shareholders” in the Prospectus. 3. Renxiang Biotechnology which is held as to 99.99% by Ms. Cheong Hou Iam (張昊任) (“Ms. Cheong”), is the sole general partner of, and is, pursuant to the relevant partnership agreements, entitled to exercise all voting rights in, each of Renyang Biotechnology, Chengzhen Health, Jiarun Tongchuang, Jiarun Hechuang, Zhuhai Meijirui, Jiarun Xinchuang and Xinhui Runkang. Each of Renyang Biotechnology, Chengzhen Health and Jiarun Tongchuang is owned as to 99% by China True Health Medical Technology Co., Ltd. (中國真健康醫療科技有限公司) (“China True Health Medical”) as its sole limited partner and 1% by Renxiang Biotechnology as its general partner. Jiarun Hechuang is owned as to 99% by China Shui Mu Medical Technology Company Limited (中國水木醫療科技有限公司) (“Shuimu Medical Technology”) as its sole limited partner and 1% by Renxiang Biotechnology as its general partner. Each of China True Health Medical and Shuimu Medical Technology is owned as to 96.67% by Ms. Cheong. As such, (i) Ms. Cheong is the ultimate beneficial owner of each of Renyang Biotechnology, Chengzhen Health, Jiarun Tongchuang, Jiarun Hechuang, Zhuhai Meijirui, Jiarun Xinchuang and Xinhui Runkang; and (ii) Ms. Cheong, Renxiang Biotechnology, China True Health Medical, Shuimu Medical Technology, Renyang Biotechnology, Chengzhen Health, Jiarun Tongchuang, Jiarun Hechuang, Zhuhai Meijirui, Jiarun Xinchuang and Xinhui Runkang are a group of Controlling Shareholders. For details of the Controlling Shareholders, please refer to the section headed “Relationship with our Controlling Shareholders – Our Controlling Shareholders” in the Prospectus.				

Pre-IPO Investors (as defined in the “History and Corporate Structure” section of the Prospectus)

<i>Name</i> ^{Note 1}	<i>No. of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>% of total issued share capital of the Company subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>Last day subject to the lock-up undertakings</i> ^{Note 2}
Sophisticated Investors				
CICC Entities				
Hengqin Guangdong Macao Deep Cooperation Zone Industrial Investment Fund (Limited Partnership)* (橫琴粵澳深度合作區產業投資基金(有限合夥)) (“Hengqin Industrial”)	1,438,669	4.04%	4.04%	June 29, 2027
Huzhou CICC Qihe Equity Investment Partnership (Limited Partnership)* (湖州中金啟合股權投資合夥企業(有限合夥)) (“CICC Qihe”)	431,601	1.21%	1.21%	June 29, 2027
Dongrong No. 1 (Zhuhai Hengqin) Equity Investment Partnership (Limited Partnership)* (東融壹號(珠海橫琴)股權投資合夥企業(有限合夥)) (“Dongrong No. 1”)	143,867	0.40%	0.40%	June 29, 2027
Subtotal	2,014,137	5.65%	5.65%	
Beijing Jinke Huiyu Venture Capital Partnership (Limited Partnership)* (北京金科匯鈺創業投資合夥企業(有限合夥)) (“Jinke Huiyu”)	1,955,547	5.49%	5.49%	June 29, 2027
Subtotal of Sophisticated Investors	3,969,684	11.14%	11.14%	
Other Pre-IPO Investors				
Hengqin Guangdong-Macao Development & Investment Co., Ltd.* (橫琴粵澳開發投資有限公司) (“Guangdong-Macao Investment”)	2,877,337	8.07%	8.07%	June 29, 2027
Zhuhai Taike Maidi Technology Development Center (Limited Partnership)* (珠海泰科麥迪科技發展中心(有限合夥)) (“Taike Maidi”)	1,440,000	4.04%	4.04%	June 29, 2027

<i>Name</i> ^{Note 1}	<i>No. of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>% of total issued share capital of the Company subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>Last day subject to the lock-up undertakings</i> ^{Note 2}
KIP Entities				
JingDe (Guangzhou) Equity Investment Partnership (LP)* (景得(廣州)股權投資合夥企業(有限合夥)) (“ JingDe (Guangzhou) ”)	673,090	1.89%	1.89%	June 29, 2027
KIP (ZhangJiaGang) Venture Capital LLP* (韓投(張家港)股權投資合夥企業(有限合夥)) (“ KIP (ZhangJiaGang) ”)	673,090	1.89%	1.89%	June 29, 2027
Subtotal	1,346,180	3.78%	3.78%	
Ligong Innovation Entities				
Beijing New Energy Technology Innovation Fund (Limited Partnership)* (北京新動能科技創新基金(有限合夥)) (“ Beijing New Energy ”)	795,470	2.23%	2.23%	June 29, 2027
Qingdao Rongyu Venture Capital Fund Partnership (Limited Partnership)* (青島榮昱創業投資基金合夥企業(有限合夥)) (“ Qingdao Rongyu ”)	259,840	0.73%	0.73%	June 29, 2027
Subtotal	1,055,310	2.96%	2.96%	
Beijing Shuimu Dongfang Medical Robotic Technology Innovation Center Co., Ltd.* (北京水木東方醫用機器人技術創新中心有限公司) (“ Shuimu Dongfang ”)	1,038,060	2.91%	2.91%	June 29, 2027
Gaorong Ventures Entities				
Beijing Gaorong Phase IV Kangteng Equity Investment Partnership (Limited Partnership)* (北京高榕四期康騰股權投資合夥企業(有限合夥)) (“ Gaorong Phase IV ”)	696,510	1.95%	1.95%	June 29, 2027
Chengdu Tianfu New Area Gaorong Phase IV Kangyong Investment Partnership (Limited Partnership)* (成都市天府新區高榕四期康永投資合夥企業(有限合夥)) (“ Kangyong Investment ”)	122,904	0.34%	0.34%	June 29, 2027
Subtotal	819,414	2.30%	2.30%	

<i>Name</i> ^{Note 1}	<i>No. of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>% of total issued share capital of the Company subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>Last day subject to the lock-up undertakings</i> ^{Note 2}
Zhuhai Gree Group Entities				
Zhuhai Hengqin Golden Investment Venture Capital Fund Partnership (L.P.)* (珠海橫琴金投創業投資基金合夥企業(有限合夥)) (“ Hengqin Golden Investment ”)	535,420	1.50%	1.50%	June 29, 2027
Zhuhai Ligao No. 2 Equity Investment Fund Partnership (Limited Partnership)* (珠海力高貳號股權投資基金合夥企業(有限合夥)) (“ Ligao No. 2 ”)	198,870	0.56%	0.56%	June 29, 2027
Subtotal	734,290	2.06 %	2.06 %	
Taiping (Shenzhen) Medical and Health Industry Private Equity Investment Fund Partnership (Limited Partnership)* (太平(深圳)醫療健康產業私募股權投資基金合夥企業(有限合夥)) (“ Taiping Medical Investment Fund ”)	719,335	2.02%	2.02%	June 29, 2027
Beijing Zhongguancun Zhiyou Investment Partnership (L.P.) (北京中關村智友投資合夥企業(有限合夥)) (“ Zhongguancun Zhiyou ”)	664,900	1.87%	1.87%	June 29, 2027
Beijing Jingantai Technology Development Co., Ltd.* (北京京安泰科技發展有限公司) (“ Beijing Jingantai ”)	615,030	1.73%	1.73%	June 29, 2027
Hengqin Shenhe Industrial Investment Co., Ltd.* (橫琴深合產業投資有限公司) (“ Hengqin Shenhe Industrial Investment ”)	431,601	1.21%	1.21%	June 29, 2027
Beijing Shuimu Linghang Entrepreneurship Investment Center (Limited Partnership)* (北京水木領航創業投資中心(有限合夥)) (“ Shuimu Linghang ”)	249,340	0.70%	0.70%	June 29, 2027
Novel Robotics Limited (諾威機器人有限公司) (“ Novel Robotics ”)	207,780	0.58%	0.58%	June 29, 2027
X Technology Fund, L.P. (“ X Technology ”)	207,780	0.58%	0.58%	June 29, 2027

<i>Name</i> ^{Note 1}	<i>No. of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>% of total issued share capital of the Company subject to lock-up undertakings upon Listing</i> ^{Note 2}	<i>Last day subject to the lock-up undertakings</i> ^{Note 2}
Zhuhai Huajin Lingyue Intelligent Manufacturing Industry Investment Fund (Limited Partnership)* (珠海華金領越智能製造產業投資基金(有限合夥)) (“ Huajin Lingyue ”)	198,870	0.56%	0.56%	June 29, 2027
Zhuhai Hengqin Xinti Investment Partnership (Limited Partnership)* (珠海橫琴辛醴投資合夥企業(有限合夥)) (“ Hengqin Xinti ”)	198,870	0.56%	0.56%	June 29, 2027
Beijing Dongsheng Bozhan Science & Technology Development Co., Ltd.* (北京東升博展科技發展有限公司) (“ Dongsheng Bozhan ”)	178,980	0.50%	0.50%	June 29, 2027
Beijing Lide Gongchuang Intelligent Robotic Technology Co., Ltd.* (北京立德共創智能機器人科技有限公司) (“ Lide Gongchuang ”)	83,110	0.23%	0.23%	June 29, 2027
Beijing Deruida Wealth Technology Management Center (Limited Partnership)* (北京德睿達財富科技管理中心(有限合夥)) (“ Deruida Wealth ”)	67,310	0.19%	0.19%	June 29, 2027
Shenzhen Ruisheng Equity Investment Fund Partnership (Limited Partnership)* (深圳瑞昇股權投資基金合夥企業(有限合夥)) (“ Shenzhen Ruisheng ”)	19,890	0.06%	0.06%	June 29, 2027
Subtotal of other Pre-IPO Investors	13,153,387	36.90%	36.90%	
Subtotal of all Pre-IPO Investors	17,123,071	48.04%	48.04%	
* <i>For identification purposes only</i> <i>Notes:</i> 1. <i>Please refer to the section headed “History and Corporate Structure — Pre-IPO Investments – Information about the Pre-IPO Investors” in the Prospectus for details of the Pre IPO Investors.</i> 2. <i>The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.</i>				

PLACEE CONCENTRATION ANALYSIS

Placees*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued share capital upon Listing
Top 1	198,000	6.17%	5.55%	198,000	0.56%
Top 5	735,040	22.91%	20.62%	735,040	2.06%
Top 10	1,210,280	37.72%	33.95%	1,210,280	3.40%
Top 25	2,005,360	62.51%	56.26%	2,005,360	5.63%

Note:

* *Ranking of placees is based on the number of H Shares allotted to the placees.*

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued share capital upon Listing
Top 1	0	N/A	N/A	14,959,232	41.96%
Top 5	0	N/A	N/A	23,246,253	65.21%
Top 10	0	N/A	N/A	28,239,507	79.22%
Top 25	735,040	22.91%	20.62%	32,647,033	91.58%

Note:

* *Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders*	Number of H Shares allotted	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing	% of total issued share capital upon Listing
Top 1	0	N/A	N/A	14,959,232	41.96%
Top 5	0	N/A	N/A	23,246,253	65.21%
Top 10	0	N/A	N/A	28,239,507	79.22%
Top 25	735,040	22.91%	20.62%	32,647,033	91.58%

Note:

* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.*

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, a total of 128,208 valid applications made by the public will be conditionally allocated on the basis set out below:

Pool A			
Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of H Shares applied for
20	41,427	829 out of 41,427 applicants to receive 20 H Shares	2.00%
40	7,588	209 out of 7,588 applicants to receive 20 H Shares	1.38%
60	27,564	912 out of 27,564 applicants to receive 20 H Shares	1.10%
80	2,610	99 out of 2,610 applicants to receive 20 H Shares	0.95%
100	2,326	98 out of 2,326 applicants to receive 20 H Shares	0.84%
120	1,081	50 out of 1,081 applicants to receive 20 H Shares	0.77%
140	894	44 out of 894 applicants to receive 20 H Shares	0.70%
160	789	41 out of 789 applicants to receive 20 H Shares	0.65%
180	666	37 out of 666 applicants to receive 20 H Shares	0.62%
200	5,197	298 out of 5,197 applicants to receive 20 H Shares	0.57%
300	5,819	402 out of 5,819 applicants to receive 20 H Shares	0.46%
400	2,139	169 out of 2,139 applicants to receive 20 H Shares	0.40%
500	1,281	112 out of 1,281 applicants to receive 20 H Shares	0.35%
600	966	92 out of 966 applicants to receive 20 H Shares	0.32%
700	1,574	160 out of 1,574 applicants to receive 20 H Shares	0.29%
800	737	80 out of 737 applicants to receive 20 H Shares	0.27%
900	448	52 out of 448 applicants to receive 20 H Shares	0.26%
1,000	2,980	357 out of 2,980 applicants to receive 20 H Shares	0.24%
2,000	2,421	398 out of 2,421 applicants to receive 20 H Shares	0.16%
3,000	1,755	347 out of 1,755 applicants to receive 20 H Shares	0.13%
4,000	1,468	332 out of 1,468 applicants to receive 20 H Shares	0.11%
5,000	1,032	258 out of 1,032 applicants to receive 20 H Shares	0.10%
6,000	774	211 out of 774 applicants to receive 20 H Shares	0.09%
7,000	581	170 out of 581 applicants to receive 20 H Shares	0.08%
8,000	794	246 out of 794 applicants to receive 20 H Shares	0.08%
9,000	455	149 out of 455 applicants to receive 20 H Shares	0.07%
10,000	2,874	986 out of 2,874 applicants to receive 20 H Shares	0.07%
20,000	1,760	829 out of 1,760 applicants to receive 20 H Shares	0.05%
30,000	1,667	945 out of 1,667 applicants to receive 20 H Shares	0.04%
Total	<u>121,667</u>	Total number of Pool A successful applicants: 8,912	

Pool B

Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of H Shares applied for
40,000	2,994	20 H Shares	0.05%
50,000	744	20 H Shares plus 106 out of 744 applicants to receive an additional 20 H Shares	0.05%
60,000	524	20 H Shares plus 144 out of 524 applicants to receive an additional 20 H Shares	0.04%
70,000	341	20 H Shares plus 135 out of 341 applicants to receive an additional 20 H Shares	0.04%
80,000	314	20 H Shares plus 161 out of 314 applicants to receive an additional 20 H Shares	0.04%
90,000	171	20 H Shares plus 107 out of 171 applicants to receive an additional 20 H Shares	0.04%
100,000	281	20 H Shares plus 204 out of 281 applicants to receive an additional 20 H Shares	0.03%
120,000	199	20 H Shares plus 184 out of 199 applicants to receive an additional 20 H Shares	0.03%
140,000	145	40 H Shares plus 16 out of 145 applicants to receive an additional 20 H Shares	0.03%
160,000	127	40 H Shares plus 36 out of 127 applicants to receive an additional 20 H Shares	0.03%
178,240	701	40 H Shares plus 305 out of 701 applicants to receive an additional 20 H Shares	0.03%
Total	<u>6,541</u>	Total number of Pool B successful applicants: 6,541	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated June 22, 2026 issued by Guangdong True Health Medical Technology Development Co., Ltd. (廣東真健康醫療科技開發股份有限公司) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall, in their sole and absolute discretion, be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Tuesday, June 30, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Immediately following the completion of the Global Offering, an aggregate of 15,205,874 H Shares or approximately 42.66% of the total issued share capital of the Company will be held in the public hands. For details of the Shareholders that are not counted towards the public float, please refer to the section headed “History and Corporate Structure – Public Float” in the Prospectus. Therefore, the number of Shares in the public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 19A.13A of the Listing Rules.

Pursuant to the applicable PRC law, within the 12 months following the Listing Date, all existing Shareholders (including the Pre-IPO Investors) cannot dispose of any of the Shares held by them. As such, the H Shares held by the existing Shareholders (including the Pre-IPO Investors) upon the Listing shall not be counted towards the free float of the H Shares of the Company at the time of Listing. Based on an Offer Price of HK\$126.20 per Offer Share, the Company will satisfy with the free float requirement under Rule 19A.13C(1)(a) of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the H shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, June 30, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, June 30, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, June 30, 2026 (Hong Kong time). The H Shares will be traded in board lots of 20 H Shares each, and the stock code of the H Shares will be 2697.

By order of the Board
Guangdong True Health Medical Technology Development Co., Ltd.
Ms. Cheong Hou Iam
Chairperson, Executive Director and General Manager

Hong Kong, June 29, 2026

As of the date of this announcement, the Board comprises: (i) Ms. Cheong Hou Iam, Ms. Chen Miaoping and Ms. Guo Jian as executive Directors; (ii) Ms. Mo Jinling as non-executive Director; and (iii) Dr. Liu Lianggang, Mr. Ng Kun Seng Chris and Mr. Ma Jianming as independent non-executive Directors.